Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasm Metastasis 40Leukemia, Myeloid, Acute 35Lung Neoplasms 34Breast Neoplasms 32Multiple Myeloma 25Carcinoma, Non-Small-Cell Lung 25Colorectal Neoplasms 23Prostatic Neoplasms 21Pancreatic Neoplasms 20Carcinoma, Renal Cell 19Melanoma 18Lymphoma 16Urinary Bladder Neoplasms 15Triple Negative Breast Neoplasms 15Ovarian Neoplasms 14Myelodysplastic Syndromes 14Burkitt Lymphoma 13Lymphoma, Large B-Cell, Diffuse 11Squamous Cell Carcinoma of Head and Neck 10Sarcoma 10Leukemia, Lymphocytic, Chronic, B-Cell 10Glioma 10Fallopian Tube Neoplasms 10Mouth Neoplasms 9Endometrial Neoplasms 9Carcinoma, Transitional Cell 9Carcinoma, Hepatocellular 9Carcinoma 9Oropharyngeal Neoplasms 8Lymphoma, T-Cell 8

Interventions

Specimen Handling 1Biopsy 13-aminopyridine-2-carboxaldehyde thiosemicarbazone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Serous Adenocarcinoma × Specimen Handling × 30 days × Clear all
NCT04494113 2026-05-13

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Active not recruiting
12 enrolled
Gynecologic

Endometrial Serous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡